Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AMRS > SEC Filings for AMRS > Form 8-K on 25-Sep-2013All Recent SEC Filings

Show all filings for AMYRIS, INC.

Form 8-K for AMYRIS, INC.


Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities

Item 1.01. Entry into a Material Definitive Agreement.

Securities Purchase Agreement

On September 20, 2013, Amyris, Inc. (the "Company") entered into that certain Securities Purchase Agreement (the "SPA") for the sale of up to $5.0 million in principal amount of the Company's unsecured convertible notes (the "Notes") to Naxyris, S.A. ("Naxyris"), an existing stockholder of the Company. The Company entered into the SPA to provide additional cash availability if needed before the closing of a convertible note financing, which is pending certain closing conditions, including a final regulatory approval. The SPA contemplates that the Notes may be issued in one or more closings to occur at the option of the Company at any time prior to October 31, 2013, following the satisfaction of certain closing conditions, including a requirement that the Company pay an availability fee of $250,000 to Naxyris.

The Company may prepay any Notes issued under the SPA at any time, and if not prepaid, the Notes are due: (i) initially on the earlier of December 16, 2013 or the Tranche I Closing Date (as such term is defined in that certain Securities Purchase Agreement, dated as of August 8, 2013 (the "Purchase Agreement"), by and among the Company and the other parties thereto) (the "Initial Maturity Date"), and (ii) if not paid on or before the Initial Maturity Date, on the earlier of the five-year anniversary of the Initial Maturity Date and the date on which the Company obtains a quarter-end cash balance of $50.0 million. The Notes accrue interest of 10% per annum, payable quarterly in arrears (paid in kind), from the Initial Maturity Date until converted or repaid. Upon repayment of the Notes, the Company is also obligated to pay Naxyris a borrowing fee equal to the product of (i) the total principal amount of the Notes outstanding divided by $5.0 million, multiplied by (ii) $250,000 (the "Borrowing Fee").

The Notes, including the Borrowing Fee and any accrued interest, are convertible into the Company's common stock, $0.0001 par value per share (the "Common Stock") at any time after the Initial Maturity Date and prior to the final maturity date, at a conversion price per share equal to $2.57 the consolidated closing bid price of the Common Stock on NASDAQ on September 19, 2013, subject to adjustment based on proportional adjustments to outstanding Common Stock and certain dividends and distributions. The Notes include standard covenants and events of default resulting in acceleration of indebtedness, including failure to pay, bankruptcy and insolvency, and breaches of the covenants in the SPA and Notes.

Additional Agreements

The SPA also requires the Company to enter into an Amendment No. 4 to Amended and Restated Investors' Rights Agreement (the "Rights Agreement Amendment" and the underlying agreement, as amended, the "Rights Agreement"), and, under the Notes, unless waived by Naxyris, the Company agreed to register the Common Stock issuable upon conversion of the Notes in accordance with the Rights Agreement if the Notes are not repaid by the Initial Maturity Date. Under the Rights Agreement, certain holders of the Company's outstanding securities can request the filing of a registration statement under the Securities Act of 1933, as amended (the "Act"), covering the shares of Common Stock held by (or issued upon conversion of other Company securities, including the Notes, held by) the requesting holders. Further, under the Rights Agreement, if the Company registers securities for public sale, the Company stockholders with registration rights under the Rights Agreement have the right to include their shares of Common Stock in the registration statement. Additionally, holders of the Company's outstanding securities with registration rights under the Rights Agreement can request that the Company register all or a portion of their Common Stock on Form S-3 if the Company is eligible to file a registration statement on Form S-3 and the aggregate price to the public of the shares offered is at least $2,000,000. The Rights Agreement Amendment would extend such rights under the Rights Agreement to the Common Stock issuable upon conversion of the Notes.

Item 3.02. Unregistered Sales of Equity Securities.

The information contained in Item 1.01 above is incorporated herein by reference.

The proposed sale and issuance of the Notes as disclosed in Item 1.01 of this Current Report on Form 8-K is intended to be exempt from registration under the Act in reliance on Section 4(2) of the Act and Rule 506 of Regulation D promulgated under the Act.

  Add AMRS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AMRS - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.